Novan's Stock Surges As SB206 Can Potentially Shorten Duration Of Contagious Skin Disease

  • Novan Inc NOVN has announced positive topline efficacy and safety results from the B-SIMPLE4 Phase 3 trial evaluating SB206, a topical antiviral gel, for the treatment of molluscum contagiosum.
  • Molluscum is a common, contagious skin infection caused by the molluscipoxvirus.
  • The trial met its primary endpoint with 32.4% of the patients in the SB206 arm (n=444) achieving complete clearance of all lesions at Week 12, versus 19.7 in the vehicle arm (n=447).
  • Secondary endpoints - 43.5% achieved a lesion count of 0 or 1 at week 12 versus 24.6% in the vehicle arm; 43% exhibited more than 90% clearance of lesions at Week 12, compared to 23.9%.
  • 19.6% showed complete clearance of all lesions at Week 8 against 11.6% in the vehicle group.
  • The Company will host a video webcast today at 8:00 a.m. ET.
  • Price Action: NOVN shares are up 22.6% at $11.08 during the premarket session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefsHealth CarePharmaceuticalsSkin Disorder
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!